Results 121 to 130 of about 2,626 (203)

The tralokinumab story: Nothing is ever simple [PDF]

Journal of Allergy and Clinical Immunology, 2019
openaire   +2 more sources

Transitioning from Cyclosporine to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Prospective Real-World Comparison of Direct Switch vs. Short Overlap. [PDF]

J Pers Med
Ureña-Paniego C, Sanabria-de la Torre R, Arias-Santiago S, Montero-Vílchez T.   +3 more
europepmc   +1 more source

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry. [PDF]

Allergy
van der Gang LF, Boesjes CM, Zuithoff NPA, Haeck I, Bacoş-Cosma O, Loman L, Atash K, Harbers V, Stadhouders S, Oosting AJ, van Lynden-van Nes AMT, Politiek K, Gostynski A, Christoffers WA, Garritsen FM, Flinterman A, Touwslager WRH, Velstra B, Stewart SM, van Erp FC, Galimont-Collen AFS, Schuttelaar MA, de Graaf M, de Bruin-Weller MS.   +23 more
europepmc   +1 more source

Effectiveness and safety of tralokinumab in a patient with severe atopic dermatitis and hepatitis B virus. [PDF]

An Bras Dermatol
Olivares-Guerrero M, Jiménez-Sánchez A, Aparicio-Domínguez M, Chicharro P.   +3 more
europepmc   +1 more source

Utilization and predictors of use of immunomodulators for atopic dermatitis: A cohort study. [PDF]

JAAD Int
Anand P, Mostaghimi A, Glynn R, Jin Y, Merola JF, Silverberg JI, Rosmarin DM, Sidbury R, Landon J, Schneeweiss MC.   +9 more
europepmc   +1 more source

Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials. [PDF]

Am J Clin Dermatol
Mayo T, Silverberg JI, Armstrong A, Guttman-Yassky E, Blauvelt A, Esdaile B, Kabashima K, Gooderham M, Kircik L, Schneider S, Bennike N, von Eyben R, Martel BC, Røpke MA, Katoh N, Alexis AF.   +15 more
europepmc   +1 more source

Tralokinumab‐induced injection‐site reactions

Contact Dermatitis
Axel De Greef, Marie Baeck
openaire   +3 more sources

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions. [PDF]

Allergy
de Bruin-Weller MS, Boesjes CM, Achten RA, Beck LA, Irvine AD, Vestergaard C, de Graaf M, van Wijk F, Bakker DS, Weidinger S.   +9 more
europepmc   +1 more source

Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1 [PDF]

Blauvelt, Andrew, Cork, Michael J., Katoh, Norito, Mark, Thomas, Schneider, Shannon K. R., Silverberg, Jonathan I., Simpson, Eric L., Wollenberg, Andreas   +7 more
core   +1 more source

The molecular mechanism of the adverse effects of the biological and small molecular drugs in the therapy of inflammatory skin diseases - psoriasis and atopic dermatitis. [PDF]

Ann Med
Lemiesz P, Nowowiejska-Purpurowicz J, Flisiak I.   +2 more
europepmc   +1 more source